In a histology-agnostic phase 2 trial of patients with BM, including seven with NSCLC (of whom two had EGFR mutations and one had an ALK rearrangement), the overall intracranial benefit rate of pembrolizumab was 42.1%, and 43% of patients with NSCLC had an intracranial response, which is consistent with our results [18]. Here, ALK is linked to non-small cell lung carcinoma.